TY - JOUR T1 - Retrospective screening for SARS-CoV-2 among 5,800 hospitalizations related to influenza-like illness during the 2018-19 pre-pandemic and 2019-2020 pandemic influenza seasons in the VAHNSI network, Spain JF - medRxiv DO - 10.1101/2021.05.24.21257402 SP - 2021.05.24.21257402 AU - Ainara Mira-Iglesias AU - Beatriz Mengual-Chuliá AU - Laura Cano AU - Javier García-Rubio AU - Miguel Tortajada-Girbés AU - Mario Carballido-Fernández AU - Juan Mollar-Maseres AU - Germán Schwarz-Chavarri AU - Sandra García-Esteban AU - Joan Puig-Barberà AU - Javier Díez-Domingo AU - F. Xavier López-Labrador AU - for the Valencia Hospital Network for the Study of Influenza and Respiratory Viruses Disease Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/05/24/2021.05.24.21257402.abstract N2 - On March 9 2020 the WHO Global Influenza Program (GIP) asked participant sites on the Global Influenza Hospital Surveillance Network (GIHSN) to contribute to data collection concerning severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We re-analysed 5,833 viral RNA archived samples collected prospectively from hospital admissions for influenza-like illness (ILI) in the Valencia Region of Spain by the VAHNSI network (4 hospitals, catchment area population 1,118,732) during the prepandemic 2018/2019 (n=4,010) and pandemic 2019/2020 (n=1,823) influenza seasons, for the presence of SARS-CoV-2. We did not find evidence for community-acquired SARS-CoV-2 infection in hospital admissions for ILI in our region before early March 2020.Competing Interest StatementDr. LOPEZ-LABRADOR reports the work in FISABIO-Public Health was partly funded by Sanofi Pasteur. Sanofi Pasteur did not participate in the design, conduct of the study, analysis or decision to publish the results. Dr. Mengual-Chulia reports grants from Sanofi Pasteur, during the conduct of the study. Dr. Mira-Iglesias reports other from Sanofi Pasteur, during the conduct of the study; other from Sanofi Pasteur, outside the submitted work. Dr. DIEZ-DOMINGO reports grants from SANOFI-PASTEUR, during the conduct of the study; and SP supported teaching activities from my institution.Funding StatementFXLL and BMC are supported by the CIBEResp, Instituto de Salud Carlos III, Spain. Data collection was partially supported by a grant from the Foundation for Influenza Epidemiology (FIE), which supports the Global Influenza Hospital Surveillance Network (see www.gihsn.org for more details). The sponsor did not participate in the study design, data analysis and interpretation, in the writing of the manuscript or in the decision to submit the manuscript for publishing.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics Research Committee of the Direccion General de Salud Publica-Centro Superior de Investigacion en Salud Publica (DGSP-CSISP) previously approved the protocol for the study of respiratory viruses in the VANSHI network.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available under reasonable request ER -